{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T07:53:50Z","timestamp":1772265230046,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40261-026-01526-2","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:42:10Z","timestamp":1770997330000},"page":"293-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Consequences Analysis of Biologic Treatments for Moderate-to-Severe Crohn\u2019s Disease Using Real-World Transition Probability and Cost Data in Thailand"],"prefix":"10.1007","volume":"46","author":[{"given":"Thanaboon","family":"Chaemsupaphan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onuma","family":"Sattayalertyanyong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khachen","family":"Kongpakwattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nichcha","family":"Subdee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritsana","family":"Chuenprapai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5867-0312","authenticated-orcid":false,"given":"Julajak","family":"Limsrivilai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"1","key":"1526_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0156-2","volume":"6","author":"G Roda","year":"2020","unstructured":"Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn\u2019s disease. Nat Rev Dis Primers. 2020;6(1):22.","journal-title":"Nat Rev Dis Primers"},{"issue":"10080","key":"1526_CR2","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","volume":"389","author":"J Torres","year":"2017","unstructured":"Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn\u2019s disease. Lancet. 2017;389(10080):1741\u201355.","journal-title":"Lancet"},{"issue":"11","key":"1526_CR3","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1080\/13696998.2020.1803889","volume":"23","author":"P Phisalprapa","year":"2020","unstructured":"Phisalprapa P, Kositamongkol C, Limsrivilai J, Aniwan S, Charatcharoenwitthaya P, Pisespongsa P, et al. Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn\u2019s disease using real world evidence in Thailand. J Med Econ. 2020;23(11):1302\u201310.","journal-title":"J Med Econ"},{"issue":"38","key":"1526_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022216","volume":"99","author":"J Limsrivilai","year":"2020","unstructured":"Limsrivilai J, Aniwan S, Sudcharoen A, Chaisidhivej N, Prueksapanich P, Pausawasdi N, et al. Temporal trend of disease recognition, treatment paradigm, and clinical outcomes of Crohn disease in Thailand from 2000 through 2017: Is early use of thiopurines beneficial? Medicine (Baltimore). 2020;99(38):e22216.","journal-title":"Medicine (Baltimore)"},{"issue":"9853","key":"1526_CR5","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","volume":"380","author":"DC Baumgart","year":"2012","unstructured":"Baumgart DC, Sandborn WJ. Crohn\u2019s disease. Lancet (London, England). 2012;380(9853):1590\u2013605.","journal-title":"Lancet (London, England)"},{"issue":"12","key":"1526_CR6","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/ibd.20939","volume":"15","author":"J Mesterton","year":"2009","unstructured":"Mesterton J, J\u00f6nsson L, Almer SH, Befrits R, Friis-Liby I, Lindgren S. Resource use and societal costs for Crohn\u2019s disease in Sweden. Inflamm Bowel Dis. 2009;15(12):1882\u201390.","journal-title":"Inflamm Bowel Dis"},{"key":"1526_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s12913-020-05425-w","volume":"20","author":"A Zand","year":"2020","unstructured":"Zand A, Kim BJ, van Deen WK, Stokes Z, Platt A, O\u2019Hara S, et al. The effects of inflammatory bowel disease on caregivers: significant burden and loss of productivity. BMC Health Serv Res. 2020;20:556.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"1526_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10620-014-3368-z","volume":"60","author":"DN Floyd","year":"2015","unstructured":"Floyd DN, Langham S, Severac HC, Levesque BG. The economic and quality-of-life burden of Crohn\u2019s disease in Europe and the United States, 2000 to 2013: a systematic review. Dig Dis Sci. 2015;60(2):299\u2013312.","journal-title":"Dig Dis Sci"},{"issue":"9","key":"1526_CR9","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","volume":"21","author":"MJ Buie","year":"2023","unstructured":"Buie MJ, Quan J, Windsor JW, Coward S, Hansen TM, King JA, et al. Global hospitalization trends for Crohn\u2019s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses. Clin Gastroenterol Hepatol. 2023;21(9):2211\u201321.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"1526_CR10","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, D\u2019Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"issue":"12","key":"1526_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145087","volume":"10","author":"S Huoponen","year":"2015","unstructured":"Huoponen S, Blom M. A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS ONE. 2015;10(12):e0145087.","journal-title":"PLoS ONE"},{"key":"1526_CR12","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002720","author":"KL Anderson","year":"2024","unstructured":"Anderson KL, Anand R, Feuerstein JD. Insurance companies\u2019 poor adherence to guidelines for moderate-to-severe ulcerative colitis\/Crohn\u2019s disease management. Am J Gastroenterol. 2024. https:\/\/doi.org\/10.14309\/ajg.0000000000002720.","journal-title":"Am J Gastroenterol"},{"key":"1526_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.cgh.2024.06.049","volume":"23","author":"J Burisch","year":"2024","unstructured":"Burisch J, Claytor J, Hernandez I, Hou JK, Kaplan GG. The cost of inflammatory bowel disease care-how to make it sustainable. Clin Gastroenterol Hepatol. 2024;23:386\u201395.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"1526_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/ecco-jcc\/jjz003","volume":"13","author":"N Pillai","year":"2019","unstructured":"Pillai N, Dusheiko M, Maillard MH, Rogler G, Brungger B, Bahler C, et al. The evolution of health care utilisation and costs for inflammatory Bowel disease over ten years. J Crohns Colitis. 2019;13(6):744\u201354.","journal-title":"J Crohns Colitis"},{"issue":"10","key":"1526_CR15","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1111\/j.1572-0241.2005.00299.x","volume":"100","author":"MF Drummond","year":"2005","unstructured":"Drummond MF. Economic evaluation of treatment strategies in gastroenterology. Am J Gastroenterol. 2005;100(10):2143\u20135.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"1526_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","volume":"30","author":"K Bodger","year":"2009","unstructured":"Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn\u2019s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30(3):265\u201374.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1526_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","volume":"16","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231\u201350.","journal-title":"Value Health"},{"issue":"3","key":"1526_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn\u2019s disease activity index. Gastroenterology. 1976;70(3):439\u201344.","journal-title":"Gastroenterology"},{"issue":"Suppl 4","key":"1526_CR19","first-page":"S129","volume":"88","author":"R Rerknimitr","year":"2005","unstructured":"Rerknimitr R, Chalapipat O, Kongkam P, Mb PK. Clinical characteristics of inflammatory bowel disease in Thailand: a 16 years review. J Med Assoc Thailand Chotmaihet thangphaet. 2005;88(Suppl 4):S129\u201333.","journal-title":"J Med Assoc Thailand Chotmaihet thangphaet"},{"key":"1526_CR20","volume-title":"Handbook of health technology assessment in Thailand","author":"U Chaikledkaew","year":"2013","unstructured":"Chaikledkaew U, Teerawattananon Y. Handbook of health technology assessment in Thailand. 2nd ed. Thailand: Nonthaburi; 2013.","edition":"2"},{"issue":"5","key":"1526_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"1526_CR22","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","volume":"6","author":"S Singh","year":"2021","unstructured":"Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn\u2019s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(12):1002\u201314.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1526_CR23","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12962-018-0114-y","volume":"16","author":"A Hansson-Hedblom","year":"2018","unstructured":"Hansson-Hedblom A, Almond C, Borgstrom F, Sly I, Enkusson D, Troelsgaard Buchholt A, et al. Cost-effectiveness of ustekinumab in moderate to severe Crohn\u2019s disease in Sweden. Cost Eff Resour Alloc. 2018;16:28.","journal-title":"Cost Eff Resour Alloc"},{"issue":"5","key":"1526_CR24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/03007995.2019.1580094","volume":"35","author":"A Varu","year":"2019","unstructured":"Varu A, Wilson FR, Dyrda P, Hazel M, Hutton B, Cameron C. Treatment sequence network meta-analysis in Crohn\u2019s disease: a methodological case study. Curr Med Res Opin. 2019;35(5):733\u201356.","journal-title":"Curr Med Res Opin"},{"issue":"9317","key":"1526_CR25","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139.","journal-title":"Lancet"},{"issue":"8","key":"1526_CR26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"1526_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","volume":"20","author":"WJ Sandborn","year":"2022","unstructured":"Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022;20(3):578-90e4.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"1526_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/apt.13851","volume":"45","author":"SN Hong","year":"2017","unstructured":"Hong SN, Kim HJ, Kim KH, Han SJ, Ahn IM, Ahn HS. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea. Aliment Pharmacol Ther. 2017;45(2):253\u201363.","journal-title":"Aliment Pharmacol Ther"},{"issue":"20","key":"1526_CR29","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"issue":"2","key":"1526_CR30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.7314\/APJCP.2013.14.2.1115","volume":"14","author":"J Chindaprasirt","year":"2013","unstructured":"Chindaprasirt J, Wanitpongpun C, Limpawattana P, Thepsuthammarat K, Sripakdee W, Sookprasert A, et al. Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. Asian Pac J Cancer Prev. 2013;14(2):1115\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"1526_CR31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s41669-017-0053-0","volume":"2","author":"P Tanvejsilp","year":"2018","unstructured":"Tanvejsilp P, Loeb M, Dushoff J, Xie F. Healthcare resource uses and out-of-pocket expenses associated with pulmonary TB treatment in Thailand. Pharmacoecon Open. 2018;2(3):297\u2013308.","journal-title":"Pharmacoecon Open"},{"issue":"4","key":"1526_CR32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1177\/1536867X20976311","volume":"20","author":"MJ Crowther","year":"2020","unstructured":"Crowther MJ. merlin\u2014a unified modeling framework for data analysis and methods development in Stata. Stata J Promot Commun Stat Stata. 2020;20(4):763\u201384.","journal-title":"Stata J Promot Commun Stat Stata"},{"issue":"5","key":"1526_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"4","key":"1526_CR34","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40273-017-0593-2","volume":"36","author":"R Hodgson","year":"2018","unstructured":"Hodgson R, Walton M, Biswas M, Mebrahtu T, Woolacott N. Ustekinumab for treating moderately to severely active Crohn\u2019s disease after prior therapy: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018;36(4):387\u201398.","journal-title":"Pharmacoeconomics"},{"key":"1526_CR35","unstructured":"World Health Organization. Life tables: life tables by country Thailand. 2022. https:\/\/apps.who.int\/gho\/data\/view.searo.61640?lang=en. Accessed 14 Jun 2024."},{"key":"1526_CR36","unstructured":"Health Intervention and Technology Assessment: HITAP Ministry of Public Health. Standard cost list for health technology assessment. 2010. http:\/\/costingmenu.hitap.net. Accessed 14 Jun 2024."},{"key":"1526_CR37","unstructured":"Memo8. Transportation (Taxi) cost calculator. 2022. https:\/\/app.memo8.com\/taxi-meter-calculator\/. Accessed 14 Jun 2024."},{"key":"1526_CR38","unstructured":"World Bank. GNI per capita, Atlas method (current US$)\u2013Thailand. 2022. https:\/\/data.worldbank.org\/indicator\/NY.GNP.PCAP.CD?locations=TH. Accessed 14 Jun 2024."},{"issue":"5","key":"1526_CR39","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S2468-1253(23)00003-1","volume":"8","author":"J Burisch","year":"2023","unstructured":"Burisch J, Zhao M, Odes S, De Cruz P, Vermeire S, Bernstein CN, et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2023;8(5):458\u201392.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"1526_CR40","first-page":"S1","volume":"6","author":"JW Windsor","year":"2023","unstructured":"Windsor JW, Kuenzig ME, Murthy SK, Bitton A, Bernstein CN, Jones JL, et al. The 2023 Impact of inflammatory bowel disease in canada: executive summary. J Can Assoc Gastroenterol. 2023;6(Suppl 2):S1\u20138.","journal-title":"J Can Assoc Gastroenterol."},{"issue":"5","key":"1526_CR41","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(23)00062-6","volume":"8","author":"R Banerjee","year":"2023","unstructured":"Banerjee R, Raghunathan N, Pal P. Managing inflammatory bowel disease: what to do when the best is unaffordable? Lancet Gastroenterol Hepatol. 2023;8(5):396\u20138.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1526_CR42","unstructured":"The Royal Thai Government Gazette. Announcement from National Drug System Development Committee: national list of essential medicine. 2022. https:\/\/www.ratchakitcha.soc.go.th\/RKJ\/docgroup\/search_result.jsp?SID=42291293F1477AB92A037281F8E6FDE1. Accessed 10 Jun 2024."},{"issue":"8","key":"1526_CR43","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/apt.16060","volume":"52","author":"EV Loftus Jr","year":"2020","unstructured":"Loftus EV Jr, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1353\u201365.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1526_CR44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MIB.0000000000000979","volume":"23","author":"BE Sands","year":"2017","unstructured":"Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease in patients Na\u00efve to or who have failed tumor necrosis factor antagonist therapy. Inflamm Bowel Dis. 2017;23(1):97\u2013106.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01526-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01526-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01526-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:51:50Z","timestamp":1772254310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01526-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1526"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01526-2","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Limsrivilai J. has received research grants from The Janssen Pharmaceutical Companies of Johnson & Johnson. Kongpakwattana K. has received a research grant from The Janssen Pharmaceutical Companies of Johnson & Johnson. The others have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Study concept and design: Limsrivilai J., Chaemsupaphan T., Sattayalertyanyong O., and Kongpakwattana K.; Acquisition, analysis, or interpretation of data: Limsrivilai J., Chaemsupaphan T., Sattayalertyanyong O., Subdee N., Chuenprapai P., and Kongpakwattana K.; Drafting of the manuscript: Kongpakwattana K., Chaemsupaphan T.; Critical revision of the manuscript for important intellectual content: Limsrivilai J., Chaemsupaphan T., Sattayalertyanyong O., and Kongpakwattana K.; Study supervision: Limsrivilai J.; All authors have read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"This study was approved by Siriraj Institutional Review Board (Approval Si 972\/2564 [IRB2]). The study was performed in accordance with the standards of ethics outlined in the Declaration of Helsinki and reported in accordance with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All patients and caregivers provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data, analytic methods, and study materials are available to other researchers upon request to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"The code is available upon reasonable request to the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Coding Availability"}}]}}